AGTR1 and breast cancer: AT1R overexpression, which has oncogenic potential in the absence of AngII administration [1], has been documented in the luminal A and B subtypes of BC and correlated with aggressive characteristics, including increased lymph node metastasis (LMN), reduced responsiveness to neoadjuvant therapy (i.e., ET), and reduced overall survival.